Who
Shane Ward
COO & CLO
Company insider
Files Form 4 as: COO & CLO, Cidara Therapeutics; Sr VP and Chief Legal SO, Bellicum Pharmaceuticals; SVP and General Counsel, Versartis.
In numbers
- Trades disclosed
- 56
- Buys
- 1
- Sells
- 9
- Bought
- $9,840
- Sold
- $2.3M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 6 Apr 2015
- Last trade
- 7 Jan 2026
- Last filed
- 7 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Jan 2026filed 7 Jan 2026 | Cidara TherapeuticsBiotechnology | SEC FORM 4 Code D | $5.6M25,083 at $221.50 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —12,500 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —6,207 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code D | —12,500 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code D | —6,207 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code D | —12,499 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code D | —135,540 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code D | —50,000 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —12,499 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —135,540 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeutics | SEC FORM 4 Code D | $5.6M25,083 at $221.50 | filing |
| 10 Dec 2025filed 12 Dec 2025 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code M | —3,500 at $0.00 | filing |
| 10 Dec 2025filed 12 Dec 2025 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code M | —6,459 at $0.00 | filing |
| 10 Dec 2025filed 12 Dec 2025 | Cidara Therapeutics | SEC FORM 4 Code F | $3.3M15,041 at $219.60 | filing |
| 10 Dec 2025filed 12 Dec 2025 | Cidara Therapeutics | SEC FORM 4 Code M | $58K3,500 at $16.65 | filing |
| 10 Dec 2025filed 12 Dec 2025 | Cidara Therapeutics | SEC FORM 4 Code M | $130K6,459 at $20.20 | filing |
| 10 Dec 2025filed 12 Dec 2025 | Cidara Therapeutics | SEC FORM 4 Sold | $2.2M9,959 at $220.08 | filing |
| 31 Mar 2025filed 2 Apr 2025 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | Cidara Therapeutics | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.